Mark Douglas Smith, Director at Jazz Pharmaceuticals plc (JAZZ), sold 1,157 shares at $230.55 ($267K) on 2026-06-15, disclosed to the SEC on 2026-06-17.
Scheduled sale ($267k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| PHR | SELL | 2024-07-22 | $175K | — | Filing → |
| JAZZ | SELL | 2023-12-06 | $50K | — | Filing → |
| JAZZ | SELL | 2023-08-15 | $343K | — | Filing → |